Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4-Reference-Cited by-同舟云学术

Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

Published:2019-08-23 Issue:7 Volume:11 Page:1331-1340
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Griffiths Katherine¹^ORCID,Binder Uli²,McDowell William³^ORCID,Tommasi Rita⁴,Frigerio Mark³^ORCID,Darby William G.¹⁵^ORCID,Hosking Chris G.¹⁵,Renaud Lionel⁶,Machacek Matthias⁶,Lloyd Peter⁷,Skerra Arne²⁸^ORCID,Foley Michael¹⁵

Affiliation:

1. The Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Melbourne, Australia

2. XL-protein GmbH, Freising, Germany

3. Abzena, Babraham Research Campus, Cambridge, UK

4. Lonza Biologics, Slough, UK

5. AdAlta Limited, Bundoora, Australia

6. LYO-X GmbH, Basel, Switzerland

7. KinDyn Consulting Limited, West Sussex, UK

8. Lehrstuhl für Biologische Chemie, Technische Universität München, Freising, Germany

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2019.1626652

Reference28 articles.

1. Antibodies to watch in 2019

2. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

3. i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4

4. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites;Nature Communications;2024-08-22

2. Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review;Cancers;2024-07-27

3. Single-Domain Antibodies—Novel Tools to Study and Treat Allergies;International Journal of Molecular Sciences;2024-07-11

4. Long-Acting Strategies for Antibody Drugs: Structural Modification, Controlling Release, and Changing the Administration Route;European Journal of Drug Metabolism and Pharmacokinetics;2024-04-18

5. Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate;Antibody Therapeutics;2024-02-16